Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.39 |
| ▸ | ERN1 | O75460 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14303935 | 0.81 | TDP1 (0.38) | TYRTDP1ALDH1A1 | |
| SCHEMBL28154797 | 0.75 | TYR (0.48) | TYRERN1TDP1MEN1LMNA | |
| SCHEMBL11890580 | 0.75 | CES2 (0.32) | — | |
| SCHEMBL9945894 | 0.73 | TYR (0.40) | TYRERN1TDP1MEN1LMNA | |
| SCHEMBL745181 | 0.73 | ERN1 (0.46) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL584614 | 0.72 | ERN1 (0.42) | ERN1TDP1MEN1LMNATHRB | |
| SCHEMBL31306389 | 0.72 | TDP1 (0.47) | TYRERN1TDP1MEN1LMNA | |
| SCHEMBL31306390 | 0.72 | TDP1 (0.47) | TYRERN1TDP1MEN1LMNA | |
| SCHEMBL1806887 | 0.72 | TDP1 (0.47) | TYRERN1TDP1MEN1LMNA | |
| SCHEMBL12678215 | 0.72 | ACHE (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | TYR 2328/4885ERN1 2855/4885TDP1 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.